Nektar terminates collaboration agreement with Bristol-Myers Squibb for bempegaldesleukin

NEKTAR THERAPEUTICS

Parties entered letter agreement on Sept 6, 2023 to terminate the 2018 Strategic Collaboration Agreement.
Collaboration covered development of bempegaldesleukin in combination with BMS's Opdivo (nivolumab).
Global clinical development program for the combination was already ended in April 2022.
Termination effective immediately per the letter agreement.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

NEKTAR THERAPEUTICS terminated Strategic Collaboration Agreement with Bristol-Myers Squibb Company (effective 2023-09-06).

Action: termination
Agreement: collaboration
Counterparty: Bristol-Myers Squibb Company
Effective: 2023-09-06

Exact text from the filing

the parties entered into a letter agreement (the “Letter Agreement”) to terminate the Strategic Collaboration Agreement.

View on SEC.gov

85 material agreements filed in the last 30 days. Browse all material agreements →

NEKTAR THERAPEUTICS filing history →

Source: SEC EDGAR

accession 0001213900-23-075473

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.